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708Futility, Beneﬁt, and Transcatheter Aortic Valve ReplacementTranscatheter aortic valve replacement (TAVR) is a transformative innovation that provides treatment for high or prohibitive
surgical risk patients with symptomatic severe aortic stenosis who either were previously not referred for or were denied
operative intervention. Trials have demonstrated improvements in survival and symptoms after TAVR versus medical
therapy; however, there remains a sizable group of patients who die or lack improvement in quality of life soon after TAVR.
This raises important questions about the need to identify and acknowledge the possibility of futility in some patients
considered for TAVR. In this very elderly population, a number of factors in addition to traditional risk stratiﬁcation need to be
considered including multimorbidity, disability, frailty, and cognition in order to assess the anticipated beneﬁt of TAVR.
Consideration by a multidisciplinary heart valve team with broad areas of expertise is critical for assessing likely beneﬁt from
TAVR. Moreover, these complicated decisions should take place with clear communication around desired health outcomes
on behalf of the patient and provider. The decision that treatment with TAVR is futile should include alternative plans to
optimize the patient’s health state or, in some cases, discussions related to end-of-life care. We review issues to be considered
when making and communicating these difﬁcult decisions. (J Am Coll Cardiol Intv 2014;7:707–16) ª 2014 by the American
College of Cardiology FoundationThe only treatment that improves survival and quality of life
for patients with severe symptomatic aortic stenosis (AS) is
valve replacement (1,2). Until recently, however, at least one-
third of such patients did not undergo treatment due to
advanced age, left ventricular (LV) dysfunction, or numerous
comorbidities (3,4). Over the last decade, transcatheter aortic
valve replacement (TAVR) has emerged as a less invasive
alternative to surgical valve replacement (5–7). Randomized
trials have demonstrated the superiority of TAVR versus
medical therapy for patients at prohibitive surgical risk and
the noninferiority of TAVR versus surgical valve replacement
for patients at high surgical risk (8,9). TAVR is a trans-
formative innovation that has extended treatment to
numerous patients with severe AS who previously were not
referred for or were denied surgical treatment.
However, although there is a tremendous survival
advantage and symptom beneﬁt for many patients under-
going TAVR (vs. no valve replacement), growing clinical
experience demonstrates that some patients die soon after
the procedure or have little improvement in quality of life or
functional status (8–11). For some, treatment of AS does
little to alter the poor prognosis associated with numerous
comorbidities (12). Among patients at prohibitive surgical
risk treated with TAVR in the PARTNER (Placement of
Aortic Transcatheter Valve) IB trial, 30% were dead at 1 year
and approximately one-half were dead or had less than a
moderate improvement in their quality of life or New York
Heart Association (NYHA) functional class (Fig. 1) (8,10).
Registries from Europe, including treatment with the
Edwards Sapien valve (Edwards Lifesciences, Irvine, Cali-
fornia) and Medtronic CoreValve (Medtronic, Minneapolis,
Minnesota), have also demonstrated that approximately one-
quarter of patients are dead by 1 year after TAVR (13–15).Therapeutic futility has been deﬁned as a lack of medical
efﬁcacy, particularly when the therapy is unlikely to pro-
duce its intended clinical result, as judged by the physician;
or lack of a meaningful survival, as judged by the personal
values of the patient (16). Ascertaining beneﬁt versus
futility in individual patients is therefore a multifaceted
exercise that must integrate information to facilitate a
collective judgment (7,17). Considering the importance
of doing no harm and the reality of limited resources,
in each case, tough questions about whether we should
perform TAVR even if we can perform TAVR must
be asked. The latter question is technical in nature and
may be distilled into measurable facts; the former is less
straightforward and includes value judgments and uncer-
tainty, which extend beyond the individual cardiologist’s
or surgeon’s technical or clinical expertise. We will review
issues to be considered when making and communicating
these difﬁcult decisions.
Approach to the High/Prohibitive Risk
TAVR Referral
Patients with severe AS fall along a spectrum of risk for
valve replacement. For those at the low-risk end of the
spectrum, such as the 65-year-old asymptomatic patient
with normal LV function and no signiﬁcant comorbid-
ities, the preeminent question is when to perform valve
replacement, and risk stratiﬁcation is used to determine
the optimal timing of surgery (18,19). In contrast, at the
high-risk end of the spectrum, the question is more often
whether to perform valve replacement. These are the
patients whose advanced age, the number and severity of
comorbidities, and poor functional status make it
Abbreviations
and Acronyms
ADL = activities of daily living
AS = aortic stenosis
AVR = aortic valve
replacement
IADL = instrumental
activities of daily living
KCCQ = Kansas City
Cardiomyopathy
Questionnaire
LV = left ventricular
NYHA = New York Heart
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STS = Society of Thoracic
Surgery
TAVR = transcatheter aortic
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709difﬁcult to determine whether valve replacement will be
beneﬁcial (20). There is no ﬁrm line drawn bet-
ween those who will and will not beneﬁt meaningfully
from TAVR; rather, in the transitional zone, acknowl-
edgment of likely outcomes in the context of the pa-
tient’s preferences becomes central. We propose the
following framework be considered: 1) clinical risk
stratiﬁcation; 2) geriatric risk stratiﬁcation; 3) anticipated
clinical beneﬁt; and 4) assessment of patient goals and
preferences (Fig. 2).
Clinical Risk Stratiﬁcation
There are numerous ways to clinically risk stratify patients
with severe AS being considered for AVR (2). The following
are some of the factors that are associated with a marked
increase in risk (Table 1). We do not include anatomic
factors that can make a patient prohibitively high risk for
conventional surgery (e.g., porcelain aorta or hostile chest
due to previous radiation) as these factors generally do not
suggest potential futility of TAVR.
Very high STS score. The Society of Thoracic Surgeons (STS)
risk score is widely used as a starting point to stratify pa-
tients in need of aortic valve replacement, both at the clinical
and research levels. It integrates several clinical parameters
to yield predicted probabilities of mortality and major
morbidity (8,9,15). The STS score has well characterized
limitations in predicting surgical risk in elderly patients with
AS undergoing valve replacement (21), particularly in terms
of calibration (i.e., predicted risk that signiﬁcantly exceeds
observed mortality rates). Relevant to the issue of futility, a
subgroup analysis of the PARTNER I trial (inoperable
cohort B) showed that in patients with an STS predicted risk
of mortality >15%, there was no survival beneﬁt from
TAVR versus medical therapy (22). The logistic Euro-
SCORE (European System for Cardiac Operative Risk
Evaluation) is also commonly used to risk stratify patients
evaluated for TAVR and an increased score is independently
associated with worse survival after TAVR (15).
Impaired LV systolic function, low valve gradients, and
reduced stroke volume. Patients with low-ﬂow, low-
gradient, low ejection fraction severe AS with no contractile
reserve on dobutamine stress echocardiography have an
operative mortality of 22% to 36% (23,24). Although there
appears to be a survival beneﬁt with valve replacement versus
medical therapy even in those without contractile reserve,
patients with a resting mean gradient <20 mm Hg have a
markedly increased risk of 1-year mortality (23,24). A low
stroke volume index (<35 ml/m2) recently was shown to be an
independent predictor of mortality, even after adjustment for
ejection fraction, in high-risk or prohibitive risk patients un-
dergoing transcatheter or surgical valve replacement (25,26).
Whether TAVR can be done at lower risk than surgery in
these patients is a promising hypothesis that requires study.Severe myocardial ﬁbrosis. The presence and extent of
interstitial myocardial ﬁbrosis (due to chronic pressure
overload rather than infarction from coronary disease) is an
independent predictor of mortality in patients with AS
(27,28). Weidmann et al. (27) showed that in patients with
AS undergoing valve replacement, those with severe cardiac
ﬁbrosis determined by cardiac magnetic resonance imaging
pre-operatively did not experience symptomatic improve-
ment from valve replacement and had less improvement in
LV function.
Severe concomitant valve disease. Moderate to severe
mitral regurgitation has been associated with increased
mortality after TAVR at 30 days (29,30) and 1 year (30),
despite the fact that approximately one-half of the patients
with signiﬁcant pre-procedural mitral regurgitation have
improvement in regurgitation severity post-TAVR (29,30).
However, a more recent report provided somewhat conﬂict-
ing data showing that moderate
or severe mitral regurgitation was
not associated with increased 2-
year mortality in patients under-
going TAVR in the PARTNER
trial (31). With respect to tricuspid
regurgitation, there are emerging
data showing that moderate or
severe tricuspid regurgitation is an
independent predictor of increased
mortality after TAVR or sur-
gical AVR (32,33). The impact
of untreated concomitant severe
mitral or tricuspid valve disease
on symptomatic improvement
and survival after TAVR re-
quires further study.
Severe pulmonary hypertension.
The presence and severity of
pulmonary hypertension in patients with AS may reﬂect
a more advanced state of disease. Pulmonary hypertension
is an independent predictor for mortality after surgical
AVR (34) and severe pulmonary hypertension (pulmonary
artery systolic pressure >60 mm Hg) is associated with a
2-fold higher adjusted risk of short- and long-term mor-
tality in very high-risk patients undergoing TAVR (35).
Severe lung, renal, and/or liver disease. Advanced disease of
other organs is independently associated with increased
mortality in patients undergoing TAVR, including severe
obstructive lung disease, particularly when oxygen-
dependent (22,35,36); advanced chronic kidney disease
(37,38); and cirrhosis (38).
Geriatric Risk Stratiﬁcation
Beyond the traditional comorbidities, a number of age-
associated conditions are prevalent in TAVR patients and
valve replacement
Figure 1. Survival, Heart Failure Symptoms, and QoL at 1 Year in Patients Treated With TAVR in the PARTNER Trial
Data shown is from the PARTNER Trial (8–11). NYHA ¼ New York Heart Association; PARTNER ¼ Placement of Aortic Transcatheter Valve trial; QoL ¼ quality
of life; TAVR ¼ transcatheter aortic valve replacement; [’d ¼ increased.
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710are often overlooked. These include frailty, disability,
mobility impairment, cognitive impairment, mood distur-
bance, malnutrition, polypharmacy, fall risk, and social
isolation (Tables 2 and 3). A multidimensional prognostic
index on the basis of this type of comprehensive geriatric
assessment was shown to outperform traditional risk scores
in a cohort of elderly heart failure patients (39) and similar
indices are beginning to be tested in elderly TAVR patients
(40–42).
Stortecky et al. (40) and Schoenenberger et al. (41) found
that 30% to 40% of patients referred for TAVR had im-
pairments in cognitive function as assessed by the mini-
mental status examination, mobility limitation as assessed by
the timed-up-and-go test, disability as assessed by activities
of daily living (ADL), or malnutrition as assessed by the
mininutritional assessment. Each of these impairments
predicted functional decline at 6 months and major adverse
events at 1 year after adjusting for predicted risk scores.
Green et al. (42) found that disability as assessed by ADL
and malnutrition as assessed by serum albumin were espe-
cially predictive of mortality at 1 year. Slow walking speed
using the common cutoff of 0.8 m/s was almost universal
in this severely compromised patient group and did not seemto be predictive of increased risk; a more stringent cutoff of
0.5 m/s fared slightly better.
Frailty is a geriatric syndrome deﬁned as impaired resil-
ience to stressors due to subclinical impairments in multiple
organ systems, particularly the cardiovascular and musculo-
skeletal systems (43,44). It is manifest at the clinical level as
a constellation of slow walking speed, weak handgrip
strength, low physical activity, exhaustion, and weight loss,
and has been operationalized by Fried et al. (45) into a
5-item scale with 3 or more positive items required to make
the diagnosis. In particular, walking speed may be consid-
ered a “geriatric vital sign” that predicts death and major
adverse cardiac events in several groups (46–48). Frailty is
often a precursor to adverse events observed after a physio-
logical stressor (e.g., surgery).
Disability is deﬁned as inability or dependency to carry
out activities essential for independent living such as dres-
sing or eating (termed activities of daily living), taking
medications or managing ﬁnances (termed instrumental
activities of daily living [IADL]). Frail patients are at risk to
develop disability in later stages, although the 2 entities are
not interchangeable (49). Patients who have substantial
disability are less likely to be referred and less likely to derive
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Figure 2. Decision Making by the Multidisciplinary Heart Valve Team on Patients Referred for TAVR
The multidisciplinary heart valve team considers and weighs the various factors shown and makes a decision regarding whether TAVR will likely be beneﬁcial or futile.
Areas of uncertainty require clinical judgment. What factors are thought to most inﬂuence the patient’s current health status affect assessment of the anticipated
beneﬁt of TAVR. Anticipated beneﬁts or risks may clearly outweigh the other, but in some cases, there is uncertainty when patient goals and preferences are especially
important to incorporate into decision making regarding whether to perform TAVR. AS ¼ aortic stenosis; other abbreviations as in Figure 1.
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711functional and quality-of-life beneﬁt after valve replacement,
regardless of whether it is technically successful. The extent
of disability burden associated with minimal-or-no likeli-
hood of beneﬁt has not yet been quantiﬁed.
The impact of frailty is less clear in the setting of TAVR;
frail patients are 3- to 5-fold less likely to survive up to 1 year
of follow-up, yet they do not necessarily experience a higher
rate of 30-day periprocedural mortality or morbidity after
TAVR (40–42). This ﬁnding is in contrast to what has been
reported in the setting of cardiac surgery where frailty
strongly predicts periprocedural complications (46,50,51)
and may be due to the less physiologically stressful nature of
TAVR versus surgery. Moreover, the feasibility of physical-
performance frailty measures in TAVR patients is debated,
with some investigators reporting that as many as 30% of
patients cannot complete the walking speed test, and others
reporting a ﬁgure <10% (40–42). Further studies will clarify
the impact of frailty on short- versus long-term outcomes
after TAVR.
At the present time, it is recommended to measure 5-m
walking speed (alone or as part of the 5-item Fried frailty
scale) before TAVR as a simple and prognostic metric of
frailtydalbeit with the proviso that the cutoff to deﬁneelevated risk is not yet known in this patient group. It is also
recommended to consider the burden of disability and
cognitive impairment with an ADL/IADL scale and a
Mini-Mental Status Exam or Montreal Cognitive Assess-
ment, respectively. Given the preliminary evidence sur-
rounding malnutrition, it would seem wise to involve a
dietician when this is suspected (40). In summary, the cur-
rent body of evidence suggests that the presence of signiﬁ-
cant disability, cognitive impairment, and/or malnutrition
tilts the decisional balance toward futility.
Anticipated Beneﬁt of TAVR
We are used to thinking about the beneﬁt of a cardiovascular
procedure, in this case valve replacement, in terms of longer
survival and improved symptoms (usually characterized as
less shortness of breath and angina for patients with AS). To
the degree that a patient’s only or main medical problem can
be ascribed to severe symptomatic AS, anticipating beneﬁt
from valve replacement is relatively straightforward. Also,
within the classiﬁcation of severe AS, there is a gradation of
severity of valve obstruction such that a more critically
narrowed valve and higher transvalvular gradient is
Table 3. Selected Geriatric Assessment Tools
Frailty
5-m gait speed
Fried’s frailty scale
Short physical performance battery
Disability
Activities of daily living
Instrumental activities of daily living
Cognitive impairment
Mini-Mental Status Examination
Table 1. Clinical Predictors of Increased Risk
Severely reduced left ventricular function
Very low transvalvular gradient (mean gradient <20 mm Hg)
Low ﬂow (low stroke volume index, <35 ml/m2)
Severe myocardial ﬁbrosis
Severe concomitant mitral and/or tricuspid valve disease
Severe pulmonary hypertension (PASP 60 mm Hg)
Severe lung disease, particularly oxygen-dependent
Advanced renal impairment (stages 4 and 5)
Liver disease
Very high STS score (predicted risk of mortality >15%)
PASP ¼ pulmonary artery systolic pressure; STS ¼ Society of Thoracic Surgeons.
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712suggestive of the potential for more pronounced clinical
beneﬁt from LV unloading after valve replacement.
In some difﬁcult cases, such as when there is severe
concomitant lung disease (particularly with a low B-type
natriuretic peptide level) or LV dysfunction with low
transvalvular gradients, some clinicians have found it useful
to perform a balloon aortic valvuloplasty to assess for any
clinical improvement as demonstrated by an increase in
6-min walk distance and improved symptoms (52). This
may suggest that whatever else may be wrong with the pa-
tient, the AS is at least contributing in a substantive way to
the patient’s functional and symptomatic impairment and
that TAVR may be of beneﬁt. Even with the aid of assessing
one’s response to a “diagnostic valvuloplasty,” anticipating
beneﬁtdpromotion and enhancement of well-beingdfrom
TAVR is often complex and difﬁcult to predict given the
very elderly population with numerous comorbidities and
poor functional status (Fig. 2).
With respect to mortality, in the inoperable cohort of the
PARTNER trial, patients with an STS score >15% had no
survival beneﬁt from TAVR versus medical management
(22) (Fig. 3). Arnold et al. (53) have proposed a score to
predict a poor clinical outcome at 6 months after TAVR
deﬁned as death, Kansas City Cardiomyopathy Question-
naire (KCCQ) <45 (comparable to NYHA functional class
IV), or a decrease of 10 points in the KCCQ from base-
line. By this deﬁnition, 35% of patients treated with TAVR
in the PARTNER trial (including both cohorts) had a poor
outcome (53). Integration of the KCCQ into the assessmentTable 2. Geriatric Predictors of Increased Risk
Advanced frailty
Disability in activities of daily living
Malnutrition
Mobility impairment
Low muscle mass and strength (“sarcopenia”)
Cognitive impairment
Mood disorders (depression, anxiety)and follow-up of patients with TAVR (it is a required
component of the TVT [Transcatheter Valve Therapy]
Registry) is an important step toward developing a broader
assessment of the effect of TAVR beyond survival and
change in NYHA functional class (54).
In addition, there may be other metrics that will help
provide a more holistic, informative picture of the impact of
TAVR on patient well-being. Going forward, it will be
important to develop models and scores for predicting poor/
good outcomes that are broadly deﬁned, patient-centered,
and particularly relevant to older adults (Fig. 4).
Patient Goals and Preferences
The assessment of futility is inherently value-driven
and must include consideration of patient’s values, goals,
and preferences. Shared decision making requires both
the patient and the provider share information, work toward
a consensus, and reach agreement on the course of action
(55). This requires communication and a provider-patient
relationship in which patients are empowered to question
therapeutic options and areas of uncertainty. This exchange
of goals and preferences assumes voluntary participation as
well as intact cognitive functioning and no signiﬁcant
depression (56,57). Healthcare goals are as individual as the
life circumstances, priorities, social setting, and beliefs of the
patients who set them. Some studies suggest that a majority
of elderly patients with heart failure are not willing to trade
survival time for improved quality of life, although this
preference is difﬁcult to predict and tends to shift with
increasing age, decreasing activity level, and worsening
symptoms (58). In general, life phase affects the views ofMontreal Cognitive Assessment
Mood disturbance
Geriatric Depression Scale
Hospital Anxiety and Depression Scale
Malnutrition
Albumin
Mininutritional assessment
Polypharmacy
Fall risk
Social isolation
Figure 3. Outcome of Patients at Prohibitive Surgical Risk in the PARTNER Trial
From the New England Journal of Medicine, Makkar RR, Fontana GP, Jilaihawi H, et al., Transcatheter aortic-valve replacement for inoperable severe aortic stenosis,
366, 1696–704. Copyright ª 2012 Massachusetts Medical Society. Reprinted with permission from the Massachusetts Medical Society. CI ¼ conﬁdence interval;
STS ¼ Society of Thoracic Surgery; other abbreviations as in Figure 1.
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713elderly patients in terms of the relative priority of quantity
or quality of life. As shown in the SUPPORT (Study
to Understand Prognoses and Preferences for Outcomes and
Risks of Treatments), older patients prefer less aggressive
care than younger patients do, but older patients may receive
even less aggressive care than they might have chosen (59).
Therefore, age may affect healthcare priorities, but
incorporating that into assumptions is apt to be misguided.
Studies have shown that patient wishes often differ from
those estimated by their families and healthcare providers
(60). Being in a more reﬂective life phase, being able to
communicate with loved ones, maintaining independence,
and preserving quality of life often become as important
as lengthening life. This is particularly true in situations
where risks, such as stroke, disability, and cognitive
impairment, increase. In the TAVR population, when
beneﬁt in symptom relief aligns with a patient’s goals, care
is not futile; however, when life prolongation and symptom
relief is not anticipated, care is futile. In situations where
disagreement about the treatment course remains, a fair
process including ethics consultation when necessary has
been proposed (61).
Multidisciplinary Heart Valve Team
Given the diversity and breadth of issues to consider when
evaluating candidates for TAVRdaside from the technical
expertise to perform the procedure successfullydit is critical
to have a multidisciplinary heart valve team to provide
additional insight and expertise to make the best decision
regarding who is most likely to beneﬁt from the procedure.
This point cannot be emphasized enough: having the clinical
volume and technical expertise should be a necessary but not
sufﬁcient requirement for a TAVR program (7,62). At thecore, the heart valve team should include cardiac surgeons,
interventional cardiologists, and noninvasive cardiologists,
each with particular expertise in complicated structural/
valvular heart disease. Consultation with imaging special-
ists, nurses, and geriatricians may be appropriate (7,63).
Dieticians and physiotherapists offer complementary ex-
pertise, and ethicists may be needed if there is disagreement
over the treatment plan. The size and composition of teams
will differ, but these areas should be represented or available
ad hoc. Every effort should be made to coordinate the eval-
uation of patients by multiple parties to limit the burden on
the patient and providers alike. Regular valve team meetings
are essential to discuss and review the patients and diagnostic
data from multiple viewpoints representing the diverse areas
of expertise delineated herein. These teams should function
much like those that exist in many institutions for tumor
boards or transplantation networks. Difﬁcult decisions inte-
grating diverse types of information are made in a collabo-
rative team. It is important for these teams to get comfortable
with the decision to not pursue TAVR in patients for whom
the anticipated beneﬁts do not outweigh the risks. This will
be an evolving area in which heart valve teams will need to
grow and mature as we learn how to better identify patients
who will beneﬁt from therapy and those who will not.
Caring for Patients for Whom TAVR
Has Been Deemed Futile
The decision not to offer TAVR should not be equated with
abandoning care, yet when no other deﬁnitive treatment
options remain, it is important for the patient, family, and
physician to be realistic about the poor prognosis and limited
life expectancy of the patient. Just as for patients with
advanced heart failure who are not candidates for a
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Irreversibly burned out LV from chronic AS 
Prior or new myocardial infarction 
Ongoing diastolic and/or systolic heart failure 
Severe concomitant lung disease 
Poor mobility 
Weakness, fatigue 
Stroke 
Progressive dementia 
Repeat procedures 
Hospital readmissions 
Institutionalization 
Disability 
Depression 
Social isolation 
Short-term death 
Obstacles to 
Benefits of TAVR 
Benefits of TAVR 
Figure 4. Obstacles to Beneﬁts of TAVR
The step-wise, progressive beneﬁts and milestones anticipated to result from TAVR may not be realized due to several potential obstacles. Fxn ¼ function;
LV ¼ left ventricle; MI ¼ myocardial infarction; abbreviations as in Figures 1 and 2.
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714ventricular assist device or transplant, the focus should be on
providing the patient and family with the appropriate
palliative care resources (64,65). Restricting symptoms are
common in the last year of life, particularly in elderly pa-
tients with chronic conditions. Chaudhry et al. (66) found
that whereas 27% of patients had physical or psychological
symptoms leading to restrictions in daily activities 5 months
before death, this rose to >55% in the month before death.
Therefore, addressing symptoms should always be a part of
the treatment plan, regardless of the futility of TAVR, and
should be expected in this patient group. As important is
ensuring continued access to clinical care, so arranging a
future clinical visit (likely back with their primary care
physician) can ease the transition between TAVR evaluation
and the decision to not pursue that treatment.
Conclusions
The transformative innovation of TAVR has provided a
tremendous opportunity to treat patients with severe
symptomatic AS at increased surgical risk, but no therapy is
universally beneﬁcial. Clinical trials and our growing expe-
rience have demonstrated that certain patients who undergo
TAVR do not beneﬁt, either due to death or a lack ofimprovement in symptoms, functionality, or quality of life.
Through clinical and geriatric risk stratiﬁcation, estimation
of clinical beneﬁt, and a discussion of the patient’s goals and
preferences, the multidisciplinary heart valve team must
discern who will beneﬁt from the procedure, who will not,
and those in the gray zone where the most patient engage-
ment is needed. When the heart team determines that
TAVR would be futile, it is imperative to emphasize the
plans for providing continuing care for patients and their
families. TAVR is an immensely promising therapeutic tool,
but as we work on technological innovations to improve the
devices, we must also use it responsibly within a framework
of care that enables shared decision making and promotes
patient goals and well-being.
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